T 0810/22 (Pembrolizumab formulation/MSD) of 24.10.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T081022.20241024
- Date of decision
- 24 October 2024
- Case number
- T 0810/22
- Petition for review of
- -
- Application number
- 12763896.3
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENTS
- Applicant name
- Merck Sharp & Dohme LLC
- Opponent name
- Strawman Limited
König Szynka Tilmann von Renesse - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 84
- Keywords
- Claims - clarity (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- T 0472/88
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the claims of the main request filed as auxiliary request 6 on 13 March 2020 and a description and figures to be adapted if necessary.